Dostarlimab: A promising new PD-1 inhibitor for cancer immunotherapy

• Published in: Journal of oncology pharmacy practice 2024-12, Vol.30 (8), p.1411-1431
• Main Authors: Farzeen, Zubaria, Khan, Rana Rashad Mahmood, Chaudhry, Ayoub Rashid, Pervaiz, Muhammad, Saeed, Zohaib, Rasheed, Shahzad, Shehzad, Behram, Adnan, Ahmad, Summer, Muhammad
• Format: Article
• Language: English
• Subjects: Antibodies, Monoclonal, Humanized - therapeutic use; Blocking antibodies; Cancer immunotherapy; Cancer therapies; Clinical trials; Colorectal cancer; Endometrial cancer; Endometrial Neoplasms - drug therapy; Endometrial Neoplasms - immunology; Endometrium; Female; Humans; Immune checkpoint inhibitors; Immune Checkpoint Inhibitors - therapeutic use; Immunotherapy; Immunotherapy - methods; Mismatch repair; Neoplasms - drug therapy; Neoplasms - immunology; Patients; PD-1 protein; Pembrolizumab; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Programmed Cell Death 1 Receptor - immunology; Rectal Neoplasms - drug therapy; Rectal Neoplasms - immunology; Rectum; Uterine cancer
• ISSN: 1078-1552; 1477-092X; 1477-092X
• DOI: 10.1177/10781552241265058

Objective Dostarlimab, a humanized monoclonal PD-1 blocking antibody, is being tested as a cancer therapy in this review. Specifically, it addresses mismatch repair failure in endometrial cancer and locally progressed rectal cancer patients. Data Sources A thorough database search found Dostarlimab clinical trials and studies. Published publications and ongoing clinical trials on Dostarlimab's efficacy as a single therapy and in conjunction with other medicines across cancer types were searched. Data Summary The review recommends Dostarlimab for endometrial cancer mismatch repair failure, as supported by GARNET studies. The analysis also highlights locally advanced rectal cancer findings. In the evolving area of cancer therapy, immune checkpoint inhibitors including pembrolizumab, avelumab, atezolizumab, nivolumab, and durvalumab were discussed. Conclusions Locally advanced rectal cancer patients responded 100% to Dostarlimab. Many clinical trials, including ROSCAN, AMBER, IOLite, CITRINO, JASPER, OPAL, PRIME, PERLA, and others, are investigating Dostarlimab in combination treatment. This research sheds light on Dostarlimab's current and future possibilities, in improving cancer immunotherapy understanding.